10x Genomics Q2 2026: Tepid Organic Uptick, Settlement Padding Persists

What happened

10x Genomics reported Q2 2026 revenue of $151 million, but $1.6 million of that came from a non-recurring Takara settlement, leaving core product and service revenue at $149.4 million—a mere 3% rise from the prior year. The bump offers a faint sign of stabilization after a 2025 marked by flat-to-declining organic sales, yet the absolute growth remains anemic and still trails the company’s own mid-single-digit aspirations. No segment detail was provided, but prior trends suggest spatial consumables again carried the load while Chromium and instrument demand stayed depressed. The report reinforces the pattern that reported results are flattered by IP monetization, masking a core business that is struggling to re-ignite organic growth. With NIH funding risk still hanging over roughly a quarter of revenue, this single data point does little to dispel the margin-of-safety concerns raised in earlier deep-value analysis.

Implication

The slight uptick in core revenue suggests that the bleeding in instruments and Chromium consumables may have eased, but it falls short of the sustained, broad-based acceleration needed to justify a premium multiple. Management’s own outlook implies 1H 2026 would resemble 2H 2025’s sluggishness, and a 3% print aligns with that tepid script. The Takara settlement, though small, is a reminder that reported margins and cash flow are still propped up by one-off gains, muddying the true earnings power. Until spatial consumables alone can reliably generate mid-single-digit total growth without settlement tailwinds, the risk of a re-rating lower under a bear case of $12–14 remains real. Investors should await evidence of durable momentum—such as two consecutive quarters of 5%+ organic growth and stabilizing instrument sales—before reconsidering the ‘potential sell’ stance.

Thesis delta

Q2 2026’s 3% organic revenue growth modestly improves the near-term trajectory from the prior year’s flat-to-down trend, but the improvement is marginal and still depends on spatial consumables offsetting weakness elsewhere. The core single-cell and instrument headwinds are unlikely to have vanished, and the reliance on non-recurring settlement revenue to flatter margins remains a red flag. Consequently, the thesis of insufficient margin of safety and unproven organic recovery is largely unshaken; a move to constructive would require multiple quarters of clean, broad-based growth acceleration.